Clinical trials

#Antibody #Clinical trials #Gene therapy #MND #Motor neurone disease #Therapeutics

Joint fund to accelerate search for motor neurone disease treatments

Medical research charity LifeArc and the MND Association have established a £1 million joint translational research fund to support researchers developing treatments for Motor Neurone Disease (MND). Despite recent advances, there is still no effective clinical treatment for MND. Each organisation is contributing £500,000 to the fund. Researchers from across… Read More

#News

#Clinical trial #Clinical trials #Data #Sitting Down With

What has the pandemic taught us about clinical trials?

The latest DDW Sponsored Sitting Down With podcast features Raj Indupuri, CEO of eClinical Solutions, and he talks to us about clinical trials. Listen to this podcast to find out why Indupuri believes ‘data is the new fuel that will drive human progress’, the effect of Covid-19 on clinical trials… Read More

#Podcasts

#Clinical trials #Podcast

What has the pandemic taught us about clinical trials? Podcast

The latest DDW Sitting Down With podcast features Raj Indupuri, CEO of eClinical Solutions, and he talks to us about clinical trials. Moving into 2021 and beyond sponsors have gained a wealth of information on how to conduct clinical trials in a global emergency. But what are the lessons… Read More

#News

#Assays #Clinical trials #Drug toxicity #Preclinical development #Toxicology

Driving the success of predictability in preclinical development 

The development of predictive preclinical assays is key to success in drug development. It is therefore critical to carefully construct biomarker studies using the most appropriate assays that better represent the complex physiology of disease for the reliable assessment of safety, efficacy, and dose predictions. To explore this topic further, Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases,… Read More

#Editor's Choice #News

#Clinical trials #Depression #Drug development #GlobalData

Novel antidepressant has blockbuster potential

Following the news that the Food and Drug Administration (FDA) has accepted Axsome Therapeutics’ new drug application (NDA) for its novel antidepressant therapy AXS-05 and granted it priority review, GlobalData commented that it would be “a blockbuster drug” by 2026, estimating global sales of approximately US$1.3 billion by 2029. Philippa… Read More

#News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Vaccine candidate #Vaccines

Novavax to participate study comparing mixed Covid-19 vaccines 

Novavax has announced its participation in a newly expanded investigator-initiated Phase II clinical trial called Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. Novavax’ recombinant protein vaccine candidate, NVX-CoV2373, is one of four Covid-19… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Vaccines

Moderna’s Covid-19 vaccine antibody persistence data published

Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, has had antibody persistence data out to six months following the second Covid-19 vaccine dose published in The New England Journal of Medicine. “We are pleased that this new data shows antibody persistence through six months following the second dose… Read More

#Covid-19 #News

#Alzheimer's #Biotechnology #Biotherapeutics #Clinical trials #Drug development #Therapeutics

Clinical Ink adds 16th concurrent Alzheimer’s study

Clinical Ink, a clinical trial technology company, has announced the addition of its 16th concurrent Phase II/III Alzheimer’s disease study, exemplifying its ongoing commitment to this therapeutic area. Clinical Ink’s platform supports the needs of sponsors working on Alzheimer’s trials by using direct collection tools that allow for flexible data… Read More

#News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Vaccines

Valneva reports positive Phase I/II data for Covid-19 vaccine

Valneva, a specialty vaccine company focused on the development and commercialisation of prophylactic vaccines for infectious diseases with significant unmet medical need, has announced positive data for Part A of the Phase I/II clinical trial of its inactivated, adjuvanted Covid-19 vaccine candidate, VLA2001. Based on this data, the company plans… Read More

#Covid-19 #News

#Animal testing #Clinical trials #Covid-19 #Research

68% of Britons want end to animal testing in UK labs

Over two-thirds of Britons want an end to animal experiments in medical research in UK labs, a new poll reveals. The YouGov survey, carried out on behalf of charity Animal Free Research UK, showed strong public support for ending animal experiments and replacing them with non-animal alternatives, such as artificial… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Pharma #Vaccines

The effect of Covid-19 solutions on the clinical trials process

Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases at ICON, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership. The world responded to the Covid-19 crisis at unprecedented speed — including vaccine development. During a pandemic, timing… Read More

#Business & Investment #Covid-19 #Exclusive Content #News

#Clinical trials #Covid-19 #Drug development #Drug discovery #Research

Hormone drugs may disarm COVID-19 spike protein

Researchers in the Abramson Cancer Center at the University of Pennsylvania have published a new preclinical study which found hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease. The study, published online in Cell Press’s iScience, showed how two… Read More

#Covid-19 #News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Clinical trials

GSK expands trial manufacturing for cell and gene therapy

Cell and Gene Therapy Catapult (CGT Catapult) has announced that GSK will leverage the CGT Catapult Stevenage facility in the UK to perform GMP cell processing to accelerate its cell and gene therapy pipeline for clinical trials. Through this agreement, GSK will improve its GMP cell processing network to advance… Read More

#News

#Biomarkers #Clinical trials #Drug development #Metabolomics #Metabolon

Life science companies collaborate for drug development

Metabolon and Cleveland Clinic have entered into multi-year collaborative agreement to accelerate research, drug development and precision medicine. Metabolon will leverage its proprietary platform to analyse a range of biologic samples to help discover metabolomic biomarkers that will deepen understanding of Cleveland Clinic’s novel discoveries, improve speed of decision-making and… Read More

#News